knowledge -WSS

knowledge

author：Wikipedia 2025-09-14 18:33:26 - browse：2822

Exact Sciences headquarters. -- biotech coverage from STAT — Exact Sciences' headquarters in Madison, Wis. Wikimedia Commons

Exact Sciences reported first-quarter revenues this week that beat market expectations, and the cancer detection company’s executives still believe they’re on track to meet expected 2024 revenue.

That’s usually good news. Yet Exact shares are down nearly 11% on Thursday, dipping to $53.12 within the first few hours of trading. During after-hours trading on Wednesday, shortly after Exact released its financial updates, shares tumbled as low as $47.24.

The seemingly paradoxical result reflects worries about a potential slowdown in future growth at Exact, a $10 billion biotech best known for Cologuard, a colon cancer screening test that detects blood and DNA from stool samples. The test, which first won regulatory approval in 2014, was designed to boost cancer screening rates by providing a more convenient alternative to colonoscopies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Abbott's new heart device gets FDA advisory panel nod

explore

WSS

Readout Newsletter: Amylyx, Aurinia, and IQVIA

Mega Millions jackpot rises to record $1.55 billion for Tuesday's drawing

Websites selling Wegovy, Zepbound ingredients targeted by FDA

Who is Magistrate Judge Moxila Upadhyaya in Trump's Jan. 6 case?

Biden calls for immediate release of Niger's president amid apparent coup

OTC birth control: A brief history of over the counter pill design

hotspot

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

ChatGPT in medicine: STAT answers readers' burning questions

Doctors on social media are being harassed and cyberbullied

State Dept. review finds Biden bears some blame for Afghanistan failures

Abbott's new heart device gets FDA advisory panel nod

Trump demands the U.S. pay no more for drugs than other countries … again

Bernie Sanders gets little from pharma CEOs on drug prices

Cancer drug shortages should be causing more outrage

ACIP vaccine advisory panel sees its vacancies filled

State Dept. review finds Biden bears some blame for Afghanistan failures

Report cites 'urgent' need to recruit more diverse clinical trial participants

focus

Congress must protect the remaining independent doctors

For BCIs, commercial hurdles may be bigger than scientific ones

ACIP vaccine advisory panel sees its vacancies filled

Congress considering partial increase for doctor pay in Medicare

Influencer to be charged after chaos erupts in New York City's Union Square

Eli Lilly reports tirzepatide MASH success during Q4 earnings

knowledge

hotspot

explore

focus